Extended Data Table 4 Other adverse events of special interest by categorya

From: Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial

  1. aThe safety population included all patients who had received at least one dose of a trial drug. Listed are events that were reported between the first dose and 135 days after the last dose. The table includes patients with immune-mediated adverse events in which immune modulating medication was initiated by category. The severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. bThere was 1 grade 5 event in the NIVO arm. This category includes the preferred terms of myositis, rhabdomyolysis, autoimmune myositis, and immune-mediated myositis. cThere was 1 grade 5 event for each arm.
Back to article page